Clay Siegall Appointed To Mirna Therapeutics’ Board Of Directors
Mirna Siegall is a biotechnology company that is focused on developing and commercializing microRNA. The company recently announced that Clay Siegall, who is the founder of Seattle Genetics, has been appointed as an outside director to the board of directors. Dr. Paul Lammers is the CEO and president of Mirna. He has stated that he is honored to have Clay as a part of the board of directors.
Dr. Siegall is equally pleased to be a part of the board of directors. He stated that he looks forward to working with the team because they will be able to provide patients with the programs that they need. He also stated that MicroRNA is an exciting area of cancer research.
About Clay Siegall
Clay Siegall started Seattle Genetics back in 1998. The company has been able to do some amazing things under Clay’s leadership. Seattle Genetics has developed numerous antibody-based therapies in order to help cancer patients. ADCETRIS® (brentuximab vedotin) is the company’s first commercial product. It was approved in August 2011.
Even before Clay Siegall started Seattle Genetics, he was involved in healthcare. He worked for the Bristol-Myers Squibb Institute from 1991 to 1997. He has also worked for the National Institutes Of Health and the National Cancer Institute. Clay has won numerous awards during his career. In 2013, he won the University of Maryland Alumnus Of The Year For Computer, Math And Natural Sciences. He was also awarded the Pacific Northwest Ernst And Young Entrepreneur Of The Year Award. Additionally, Clay is the author of over 70 publications.